SEC Form 4 · accession 0001649904-26-000015
RHYTHM PHARMACEUTICALS, INC. · RYTM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Shulman
Officer — Chief Technical Officer
Period of report
Aug 13, 2026
Accepted (ET)
Aug 17, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649904
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 13, 2026 | M | 2,024 | $6.80 | A | 20,994 | D | |
| Common Stock | Aug 13, 2026 | S | 5,079 | $119.75 | D | 15,915 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2 | $6.80 | Aug 13, 2026 | M | 2,024 | D | — | Feb 8, 2032 | Common Stock | 2,024 | 5,945 | D |
Explanation of responses
- F1The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
- F2The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.